TY - JOUR
T1 - Establishing sanctioned safe consumption sites in the United States
T2 - Five jurisdictions moving the policy agenda forward
AU - Kennedy-Hendricks, Alene
AU - Bluestein, Jenna
AU - Kral, Alex H.
AU - Barry, Colleen L.
AU - Sherman, Susan G.
N1 - Funding Information:
This study was supported by the Scattergood Foundation.
Publisher Copyright:
© 2019 American Psychiatric Association. All rights reserved.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/4
Y1 - 2019/4
N2 - Objective: Safe consumption sites enable use of pre-obtained drugs in hygienic settings where trained staff are available to respond to overdoses and connect individuals with health and social services. This study examined efforts to advance policies to establish safe consumption sites in the United States, where no sanctioned sites exist. Methods: Between April and July 2018, the authors conducted 25 telephone interviews with a purposive sample of key informants in five communities considering safe consumption site implementation. Participants included organizers and advocates, government officials, and personnel with social service and health organizations. Interview notes were analyzed by using hybrid inductive-deductive coding. Results: Key strategies for organizing support for safe consumption sites included involving people who use drugs, engaging diverse partners, supporting allies in related causes, and using various tactics to garner support from policy makers. Major barriers to adoption included identifying the right locations, uncertainty about the federal response, mistrust arising from racial injustice in drug policy, and financing. Participants identified facilitators of progress toward safe consumption site adoption, such as building on existing harm reduction programs, securing political champions, and exposing community officials to programs operating internationally. Conclusions: A window of opportunity may be opening to advance policy related to safe consumption sites; whether sanctioned sites become part of the broader policy strategy for addressing drug use and overdose in the United States will depend on the experiences of the first sites. Organizing around this issue may facilitate engagement among people who use drugs in broader conversations about drug policy.
AB - Objective: Safe consumption sites enable use of pre-obtained drugs in hygienic settings where trained staff are available to respond to overdoses and connect individuals with health and social services. This study examined efforts to advance policies to establish safe consumption sites in the United States, where no sanctioned sites exist. Methods: Between April and July 2018, the authors conducted 25 telephone interviews with a purposive sample of key informants in five communities considering safe consumption site implementation. Participants included organizers and advocates, government officials, and personnel with social service and health organizations. Interview notes were analyzed by using hybrid inductive-deductive coding. Results: Key strategies for organizing support for safe consumption sites included involving people who use drugs, engaging diverse partners, supporting allies in related causes, and using various tactics to garner support from policy makers. Major barriers to adoption included identifying the right locations, uncertainty about the federal response, mistrust arising from racial injustice in drug policy, and financing. Participants identified facilitators of progress toward safe consumption site adoption, such as building on existing harm reduction programs, securing political champions, and exposing community officials to programs operating internationally. Conclusions: A window of opportunity may be opening to advance policy related to safe consumption sites; whether sanctioned sites become part of the broader policy strategy for addressing drug use and overdose in the United States will depend on the experiences of the first sites. Organizing around this issue may facilitate engagement among people who use drugs in broader conversations about drug policy.
UR - http://www.scopus.com/inward/record.url?scp=85063999915&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063999915&partnerID=8YFLogxK
U2 - 10.1176/appi.ps.201800398
DO - 10.1176/appi.ps.201800398
M3 - Article
C2 - 30755131
AN - SCOPUS:85063999915
SN - 1075-2730
VL - 70
SP - 294
EP - 301
JO - Psychiatric Services
JF - Psychiatric Services
IS - 4
ER -